Palma, Spain and San Diego, USA, November 10, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announces the publication of subgroup analyses from its Phase 2b CaLIPSO clinical study in Kidney International Reports. CaLIPSO studied the effect of SNF472 over 52 weeks on vascular calcification in … Continue reading Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports
Copy and paste this URL into your WordPress site to embed
Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports
Palma, Spain and San Diego, USA, November 10, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announces the publication of subgroup analyses from its Phase 2b CaLIPSO clinical study in Kidney International Reports. CaLIPSO studied the effect of SNF472 over 52 weeks on vascular calcification in … Continue reading Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports